Emergent BioSolutions Secures $16.7M Contract for Ebanga™

Emergent BioSolutions Boosts Ebanga™ Development with New Funding

Emergent BioSolutions Inc. (NYSE: EBS) has made significant strides in its ongoing partnership with the Biomedical Advanced Research and Development Authority (BARDA) by securing a contract option valued at approximately $16.7 million. This collaboration is centered around the advanced development and procurement of Ebanga™ (ansuvimab-zykl), a crucial treatment for Ebola virus infections.

Details on the Contract Modification

This funding is an extension of Emergent's existing 10-year contract with BARDA, which carries a total maximum value of $704 million. The recent contract modification reflects the successful progress achieved in the Ebanga™ program, highlighting performance milestones that have triggered this latest financial commitment.

Advancing Ebola Treatment Options

Ebanga™ has been developed specifically to treat infections caused by the Zaire Ebola virus, a disease known for its high mortality rates. "Our collaboration with BARDA is vital in advancing Ebanga™ toward becoming a readily available treatment, reinforcing our commitment to public health preparedness," stated Dr. Simon Lowry, Emergent’s Chief Medical Officer. The ongoing research under this contract signifies Emergent's dedication to addressing major public health threats and offers hope to communities affected by Ebola.

Implications of the Contract for Emergent BioSolutions

The contract encompasses key activities necessary for furthering Ebanga™'s development, including critical manufacturing scale-up and various validation processes necessary for maintaining the quality and efficacy of the drug. Moreover, it includes the submission of a supplemental Biologics License Application to the U.S. Food and Drug Administration, marking a significant step toward regulatory approval.

About Ebanga™

Ebanga™ (ansuvimab-zykl) is a human monoclonal antibody directed against the glycoprotein of the Zaire ebolavirus, indicated for treating infected adults and children, including newborns born to mothers who are RT-PCR positive for Zaire ebolavirus infection. While Ebanga™ shows promise, it is crucial to note that its efficacy against other ebolavirus species and Marburgvirus is not established.

Potential Risks and Safety Information

As with any therapeutic agent, Ebanga™ carries risks. Hypersensitivity and infusion-associated reactions have been reported, stressing the importance of patient monitoring during administration. Adverse reactions may include fever, tachycardia, and gastrointestinal disturbances.

Background on Ebola Virus Disease

Ebola virus disease (EVD) represents a severe, often fatal condition, characterized by case fatality rates between 25% and 90%. It poses a significant threat to public health, especially in affected regions. The U.S. Department of Homeland Security identifies EVD as a material threat, underscoring the urgent need for effective therapeutics like Ebanga™.

About Emergent BioSolutions

Emergent BioSolutions has been a critical player in the fight against emerging and re-emerging infectious diseases for over 25 years. Committed to public health, the company develops and manufactures vaccines and therapeutics, preparing for potential health crises. Their mission centers on protecting communities by creating effective medical solutions to public health challenges. For more information regarding their initiatives and goals, refer to their [website](https://www.globenewswire.com/Tracker?data=2E1xmOxFj-7Vh_Mv2hGgw8y6Hic0j0HS-feIh9lLvDWGsPhi2jh1JFPkyedmbmbI8qJeiBiGD18KQqueQGYtK-VbDCRRVUZX7NLMJdPOddk=).

Frequently Asked Questions

What is Ebanga™ used for?

Ebanga™ is indicated for the treatment of infections caused by the Zaire Ebola virus in adults and pediatric patients.

How much is the recent contract modification worth?

The contract modification with BARDA is valued at approximately $16.7 million.

What is the total maximum value of the BARDA contract?

The total maximum value of the existing BARDA contract is $704 million.

What should be monitored during the administration of Ebanga™?

Patients should be monitored for signs of hypersensitivity and infusion-related reactions, including fever and hypotension.

How long has Emergent BioSolutions been in operation?

Emergent BioSolutions has been active for over 25 years, focusing on public health preparedness and the development of vaccines and therapeutics.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.